WST

West Pharmaceutical Services
D

WST

Arincen83/100B

West Pharmaceutical Services income statement 1985–2026

3.40B USD over the last twelve months, and 3.07B USD in fiscal year 2025.

Revenue Operating income Net income

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Revenue
3.40B3.07B2.89B2.95B2.89B2.83B2.15B1.84B1.72B1.60B1.51B
Revenue growth
+12.58%+6.26%-1.98%+2.27%+1.94%+31.86%+16.44%+7.31%+7.36%+6.04%+7.95%
Cost of revenue
2.12B1.97B1.89B1.82B1.75B1.66B1.38B1.23B1.17B1.09B1.01B
Gross profit
1.28B1.10B1.00B1.13B1.14B1.17B767.90M608.80M546.30M514.80M501.00M
Gross margin
37.59%35.89%34.65%38.38%39.47%41.45%35.77%33.02%31.80%32.17%33.20%
Research and development
75.60M74.30M69.10M68.40M58.50M52.80M46.90M38.90M40.30M39.10M36.80M
Selling, general and administrative
436.50M393.10M338.50M353.40M316.90M361.90M302.00M272.70M262.90M246.00M239.80M
Operating expenses
496.20M485.90M407.60M421.80M375.40M414.70M348.90M311.60M291.50M285.10M285.50M
780.20M617.40M594.60M710.90M763.50M758.70M419.00M297.20M254.80M229.70M215.50M
Operating income growth
+23.66%+3.83%-16.36%-6.89%+0.63%+81.07%+40.98%+16.64%+10.93%+6.59%+71.44%
Operating margin
22.97%20.09%20.56%24.09%26.46%26.80%19.52%16.12%14.83%14.35%14.28%
Interest income
10.20M17.70M19.60M28.00M5.10M1.00M1.40M3.80M2.10M1.30M1.10M
Interest expense
—600.00K2.90M8.80M7.60M8.50M8.50M8.00M8.10M7.10M6.40M
Other non-operating income
13.10M-2.10M5.60M4.80M-62.90M10.30M-300.00K3.50M-6.50M1.90M-17.50M
Pretax income
793.30M615.30M600.20M715.70M700.60M769.00M418.70M300.70M248.30M231.60M198.00M
Income tax
168.20M121.60M107.50M122.30M114.70M107.20M72.50M59.00M41.40M80.90M54.40M
Effective tax rate
21.20%19.76%17.91%17.09%16.37%13.94%17.32%19.62%16.67%34.93%27.47%
638.90M493.70M492.70M593.40M585.90M661.80M346.20M241.70M206.90M150.70M143.60M
Net income growth
+29.94%+0.20%-16.97%+1.28%-11.47%+91.16%+43.24%+16.82%+37.29%+4.94%+50.21%
Net margin
18.81%16.06%17.03%20.11%20.31%23.38%16.13%13.11%12.04%9.42%9.52%
Basic shares
71.38M72.30M73.00M74.30M74.40M74.40M73.90M74.00M73.90M73.90M73.30M
Diluted shares
71.80M72.70M73.70M75.30M75.80M76.30M75.80M75.40M75.40M75.80M75.00M
Change in diluted shares
-1.71%-1.36%-2.12%-0.66%-0.66%+0.66%+0.53%0.00%-0.53%+1.07%+1.63%
EPS (basic)
8.976.836.757.997.888.904.683.272.802.041.96
EPS (diluted)
8.916.806.697.887.738.674.573.212.741.991.91
EPS growth
+31.80%+1.64%-15.10%+1.94%-10.84%+89.72%+42.37%+17.15%+37.69%+4.19%+46.92%
Dividends per share
0.880.850.810.770.730.690.650.610.570.530.49
Dividend growth
+4.76%+4.94%+5.19%+5.48%+5.80%+6.15%+6.56%+7.02%+7.55%+8.16%+8.89%
EBITDA
966.90M770.60M743.80M844.10M808.10M879.70M518.90M403.20M353.20M326.20M286.90M
EBITDA margin
28.47%25.07%25.71%28.60%28.01%31.08%24.17%21.87%20.56%20.39%19.01%
EBIT
783.20M599.20M588.40M706.80M687.50M757.40M409.80M299.80M248.80M229.50M196.20M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Figures underlined with dots are from the company's SEC filings, where our data provider's differ.

Common questions about West Pharmaceutical Services's income statement

Source: Financial Modeling Prep